EILEAN THERAPEUTICS DOSES FIRST PATIENT WITH ZE46-0134, A SELECTIVE FLT3wt-SPARING, PAN FLT3mut INHIBITOR

Eilean Therapeutics LLC announced the initiation of human dosing in the Phase 1 clinical program of ZE46-0134, a highly potent and selective pan-FLT3 inhibitor that targets clinically relevant FLT3 mutations including the FLT3 gatekeeper mutation, while sparing the wild type form of the protein.